NCDB Analysis of Melanoma 2004–2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval

NCDB Analysis of Melanoma 2004–2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval

<b>Background:</b> The incidence of invasive melanoma is rising, and approval for the first immune checkpoint inhibitor (ICI) to treat metastatic melanoma occurred in 2011. We aim to describe the epidemiology and outcomes in recent years, sociodemographic factors associated with the pres...

Full description

Bibliographic Details
Main Authors: Sunny R. K. Singh, Sindhu J. Malapati, Rohit Kumar, Christopher Willner, Ding Wang
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
melanoma
epidemiology
healthcare disparities
immunotherapy
immune checkpoint inhibitor
real-world data
Online Access:https://www.mdpi.com/2072-6694/13/6/1455

Internet

https://www.mdpi.com/2072-6694/13/6/1455

Similar Items